Literature DB >> 32457107

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

Laurent Poirel1,2,3, Xavier Vuillemin4, Mario Juhas4, Amandine Masseron4, Ursina Bechtel-Grosch5, Simon Tiziani6, Stefano Mancini7, Patrice Nordmann4,2,3,8.   

Abstract

KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  KPC; Klebsiella pneumoniae; ceftazidime-avibactam

Mesh：

Substances：

Year:  2020        PMID： 32457107      PMCID： PMC7526841          DOI： 10.1128/AAC.00321-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates.

Authors:  Laure Diancourt; Virginie Passet; Jan Verhoef; Patrick A D Grimont; Sylvain Brisse
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Authors:  David M Livermore; Marina Warner; Dorota Jamrozy; Shazad Mushtaq; Wright W Nichols; Nazim Mustafa; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

3.  In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Liang Chen; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.

Authors:  Peera Hemarajata; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

5.  Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.

Authors:  Ghady Haidar; Cornelius J Clancy; Ryan K Shields; Binghua Hao; Shaoji Cheng; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2015-05-08       Impact factor: 5.790

7.  Rapid detection of carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Laurent Poirel; Laurent Dortet
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

8.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867

9.  Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018.

Authors:  Kati Räisänen; Irma Koivula; Heikki Ilmavirta; Santeri Puranen; Teemu Kallonen; Outi Lyytikäinen; Jari Jalava
Journal:  Euro Surveill       Date:  2019-05

10.  Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079
View more
  14 in total

1.  KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam.

Authors:  Claire Amaris Hobson; Stéphane Bonacorsi; Hervé Jacquier; Alaksh Choudhury; Mélanie Magnan; Aurélie Cointe; Béatrice Bercot; Olivier Tenaillon; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

2.  A Selective Culture Medium for Screening Ceftazidime-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa.

Authors:  Mustafa Sadek; Laurent Poirel; Camille Tinguely; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

3.  Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.

Authors:  Laurent Poirel; Mustafa Sadek; Ayda Kusaksizoglu; Patrice Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-28       Impact factor: 3.267

Review 4.  Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.

Authors:  Claire Amaris Hobson; Gautier Pierrat; Olivier Tenaillon; Stéphane Bonacorsi; Béatrice Bercot; Ella Jaouen; Hervé Jacquier; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2022-08-18       Impact factor: 5.938

5.  In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.

Authors:  Jacqueline Findlay; Céline Rens; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

6.  Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam.

Authors:  Naphat Satapoomin; Punyawee Dulyayangkul; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2022-03-16       Impact factor: 5.938

7.  Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri.

Authors:  Francois Lebreton; Brendan W Corey; Christi L McElheny; Alina Iovleva; Lan Preston; Katie R Margulieux; Robert J Cybulski; Patrick Mc Gann; Yohei Doi; Jason W Bennett
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

8.  Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.

Authors:  Marta Hernández-García; Juan Antonio Castillo-Polo; Desirèe Gijón Cordero; Blanca Pérez-Viso; María García-Castillo; Javier Saez de la Fuente; María Isabel Morosini; Rafael Cantón; Patricia Ruiz-Garbajosa
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

9.  KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.

Authors:  Jacqueline Findlay; Laurent Poirel; Mario Juhas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

Review 10.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.